Myotonic Dystrophy — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Clinical and healthcare burden of myotonic dystrophy type 1 (DM1) in the United States: a claims-based study.
Hamel Johanna I et al. — Journal of medical economics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41764034/
- 2.
A pH-responsive dual-drug nanoplatform for stromal remodeling and enhanced chemotherapy via MMP3/TGF-
Tan Tao et al. — International journal of pharmaceutics: X (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41583062/
- 3.
Metformin improves RAN protein pathology, alternative splicing, and behavioral phenotypes in SCA8 mice.
Romano Lisa El et al. — Life science alliance (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41771688/
- 4.
Child consumer-centered co-creation for the development of healthy dairy products: Comparative insights from diabetic and non-diabetic children.
Ribeiro Ana Cristina Pinesso et al. — Food research international (Ottawa, Ont.) (30 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41794495/
- 5.
Prospective Study of Video Hand Opening Time as a Quantitative Measurement of Myotonia in Patients With Myotonic Dystrophy Type 1.
Leeuwenberg Kristofoor E et al. — Neurology (14 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41747205/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
Recruiting — Phase 1 — Sanofi
https://clinicaltrials.gov/study/NCT06844214
- 2.
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
Recruiting — Phase 1 — Vertex Pharmaceuticals Incorporated
https://clinicaltrials.gov/study/NCT06185764
- 3.
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
Recruiting — Phase 1 — Dyne Therapeutics
https://clinicaltrials.gov/study/NCT05481879
- 4.
First-In-Human Study to Evaluate Single and Multiple Ascending Doses of JUV-161 in Healthy Adult Volunteers
Recruiting — Phase 1 — Juvena Therapeutics
https://clinicaltrials.gov/study/NCT06918925
- 5.
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Recruiting — Phase 2 — AMO Pharma Limited
https://clinicaltrials.gov/study/NCT05004129
- 6.
Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
Recruiting — Phase 1 — Arrowhead Pharmaceuticals
https://clinicaltrials.gov/study/NCT06138743
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Myotonic Dystrophy
Myotonic dystrophy type 1 is the most common adult-onset muscular dystrophy, causing progressive muscle weakness, myotonia (difficulty relaxing muscles), and multi-system complications including heart rhythm problems and cataracts. It is caused by a DMPK gene expansion. There is currently no cure, but management can significantly improve quality of life.
Most Recent Research
OBJECTIVES: Myotonic dystrophy type 1 (DM1) is a multi-systemic disease affecting skeletal and smooth muscle, the eye, brain, and heart. No disease-modifying therapies are available. Prior studies on clinical care and economic burden combined DM1 and DM type 2. This study describes the US DM1 population aged ≥12 years, assessed organ system involvement over time, estimated healthcare resource utilization (HCRU), associated costs, and identified predictors of high-cost status. METHODS: Linked open claims and EHR data (Clarivate) from 1 January 2015 to 25 August 2023 were analyzed. Eligible individuals had a DM1 diagnosis (index), ≥6 months pre-index data, and were aged ≥12 years; congenital DM was excluded. Organ system involvement rates up to 7 years post-index were estimated using the Kaplan-Meier method. Annual HCRU rates and costs to payers (2023 USD) were summarized by setting, type of care and specialty and compared by organ involvement. Predictors of high-cost status were evaluated using multivariable logistic regression. RESULTS: The cohort included 1,343 people with DM1. Over 7 years, most experienced neurological, gastrointestinal, cardiac, pulmonary, and/or musculoskeletal system involvement. Annually post-index, approximately 24% of patients had emergency room visits, and 15% had inpatient visits. Common specialty visits included rehabilitation (13%), cardiology (13%), and neurology (11%). Frequent device use included noninvasive positive-pressure ventilation (12%), assistive devices (7%), and oxygen therapy (4%). Mean annual total cost of care was $20,687 (SD = $122,082), primarily driven by inpatient and outpatient hospital visits. Cardiac and pulmonary complications were significant predictors of high-cost status. CONCLUSION: DM1 imposes significant clinical and economic burden, marked by extensive organ involvement and variable healthcare costs. As any patient may progress to costly cardiac or pulmonary complications, early proactive management is critical. The complexity and heterogeneity of DM1 highlight ongoing unmet needs and the importance of developing effective treatments.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.